Home Uncategorized Effect of Knowledge on Medication Adherence and INR Control Among Patients on Oral Anticoagulants: A Randomized Controlled Trial

Effect of Knowledge on Medication Adherence and INR Control Among Patients on Oral Anticoagulants: A Randomized Controlled Trial

by [email protected]

J Young Pharm
J Young Pharm
J Young Pharm

Journal of Young Pharmacists
J Young Pharm

0975-1505
Journal of Young Pharmacists India
JYP-15-1-2022_1 10.5530/jyp.15.1.01
Editorial

Effect of Knowledge on Medication Adherence and INR Control Among Patients on Oral Anticoagulants: A Randomized Controlled Trial

Anand
Shubhi

Avvaru
Deepthi

Deshpande
Anushree

[email protected]

James
Leah Abigail

Patil
Aproova S

Patted
Suresh V

Department of Pharmacy Practice, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research (KAHER), Nehru Nagar, Belagavi, Karnataka, INDIA.
Department of Cardiology, J N Medical College, A Constituent Unit of KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, INDIA.

Correspondence: Dr. Anushree Deshpande Assistant Professor, Department of Pharmacy Practice, KLE College of Pharmacy, Belagavi. KLE Academy of Higher Education and Research, Nehru Nagar, Belagavi-590010, Karnataka, INDIA.

Jan-Mar
2022
15
1
1
7

02
07
2022

28
08
2022

15
09
2022

©2022 Phcog.Net
2022
Phcog.Net
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.Background: Anticoagulants must be provided with careful monitoring and adjusted individual dose due to their narrow therapeutic index due to significant risk of medication-drug interactions, drug-food interactions, and adverse drug reactions. Regular monitoring of INR, adequate knowledge and adherence to oral anticoagulant therapy plays a vital role in achieving better therapeutic outcomes. Thus, our study aims to assess level of adherence and knowledge of the patients. Materials and Methods: A prospective interventional study, enrolled 66 patients (control 33) and intervention (33) of both IPD (Inpatient Department) or OPD (Outpatient Department) patients with thromboembolic disorders between the age of 18-65 years and who were on oral anti-coagulant therapy. Utilization of Morisky medication adherence scale (MMAS-8) and Oral Anticoagulant Knowledge (OAK) questionnaire to assess adherence and knowledge on oral anti coagulation therapy. Results: Out of 66 patients, 56.1% male patients predominate over the 43.9% female patients, most of them were of age between 41-50 years. Majority of the patients of the intervention group were highly adhered (27.3%), moderately adhered (51.5%) and have adequate knowledge (90.9%) at follow ups after providing pharmaceutical care. Therapeutic INR has been improved among 36.4% patients. Most common cause for non-adherence is forgetfulness. Conclusion: Collaboration with clinical pharmacists can increase anticoagulant adherence and provide necessary information. Anticoagulant clinics run by pharmacists have shown to be helpful in managing anticoagulation treatment for both hospitalized and outpatient patients.

Adherence
International Normalized Ratio
Knowledge
Oral anticoagulants

Anticoagulants are the .pharmaceutical agents that prevent or minimizes the risk of coagulation via prolonging the clotting of blood.1 Oral anticoagulants are broadly classified into vitamin K antagonists (VKAs) and the direct oral anticoagulants (DOACs).2 The VKAs competitively inhibit vitamin K epoxide reductase enzyme which is responsible for activating vitamin K associated in coagulant factors (factor II, vii, ix, x) and antithrombotic factors.3 Similarly, DOACs bind at the active site of coagulation enzymes and inhibit a single protease.4 Warfarin is widely used VKAs which requires continuous monitoring and often causes drug interactions.5 The DOACs drugs include dabigatran, apixaban, rivaroxaban and are expected to overcome the limitations of warfarin therapy.5 DOACs drugs have more advantages than VKAs such as few drug interactions, rapid onset of action, does not require routine coagulation monitoring, predictable pharmacokinetic profiles.2

Thrombosis is a clotting of blood in the circulatory system (veins or arteries).6 In 2010, 1 in every 4 deaths are known to be caused by thromboembolic disorders globally.7 Thromboembolic disorders include deep vein thrombosis (DVT), pulmonary embolism (PE), several cardio and cerebro vascular diseases.6 As anticoagulants are narrow therapeutic index drug, they have to be administered with monitoring and modified individual dosage regimen risk of drug-drug interactions, drug-food interactions, adverse drug reactions.8 The number of patients on anticoagulant medication has risen significantly in recent years, which requires decentralized monitoring.8 Monitoring needs include blood coagulation levels with prothrombin time (PT) to derive international normalized ratio (INR).8 Although the DOACs does not require regular monitoring which makes it convenient to use, this could leads to potential hazard due to lack of opportunity for assessment of anticoagulation in an individual, adherence and knowledge reinforcement.9 Patients with optimum knowledge and adherence to oral anticoagulant therapy are more likely to achieve optimal treatment outcomes, compared to those who do not.10 Thus our study aims to assess medication adherence and knowledge about oral anticoagulants among patients of prescribed therapy.

 

A prospective interventional study was conducted at cardiology department in tertiary care Charitable hospital. The study was conducted for the duration of six months. We enrolled 66 patients (control 33) and intervention (33) of both IPD (Inpatient Department) or OPD (Outpatient Department) patients with thromboembolic disorders between the age of 18-65 years and who were on oral anti-coagulant therapy. Patients who were unwilling to participate, loss of follow up or critically ill condition were excluded from the study. This study was initiated after the approval from the institutional ethics committee on the human subject (Ref. No. KLECOP/665/2018-19) and written informed consent was obtained from each participant before the enrolment. The enrolled patients were randomized to control and intervention group. The control group received usual standard care whereas the intervention group were counselled about the disease, its complication, plan of treatment, dosage regimen, need for the adherence to the treatment, side effects and need for follow up along with the usual standard care. The relevant data on adherence and knowledge of patient on oral anticoagulant therapy were collected using self-designed data collection form. Morisky medication adherence scale (MMAS-8) and Oral Anticoagulant Knowledge (OAK) questionnaire to assess adherence and knowledge on oral anti coagulation therapy. The patients were followed up for the duration of 2 months.

The data was analyzed for descriptive statistics using SPSS (Statistical Package for Social Sciences) version 22.0 (IBM statistics). The detailed work flow of the study has been depicted in the Figure 1.

10.5530/jyp.15.1.01/fig-1

 

A total of 66 patients were randomly enrolled in the study out of which 50% (33) were assigned to control group and 50% (33) were into intervention group. Out of 66 patients, in control 57.6% (19) were males and 42.4% (14) were females. Whereas, in intervention 54.5% (18) were males and 45.5% (15). The mean age of control group and intervention group patients is 44.4 and 43.9 years i.e.; most of them were of age between 41-50 years 27.3% (9) and 27.3% (3) respectively. The majority of patients from control group were diagnosed with rheumatic heart disease 21.2% (7), followed by MI 15.2% (5), unstable angina 12.1% (4), Vascular surgery/ prosthetic heart valve 12.1% (4), Defibrillation syndrome 9.1% (3), PE 9.1% (3), stroke 6.1% (2), DVT 3% (1), CHF 3% (1), IHD 3% (1). Likewise, MI 21.2% (7), unstable angina 15.2% (5), cerebrovascular disease 12.1% (4), Vascular surgery/ prosthetic heart valve 9.1% (3), DVT 9.1% (3), rheumatic heart disease 9.1% (3), PE 6.1% (2), stroke 6.1% (2), IHD 6.1% (2), Defibrillation syndrome 3% (1), CHF 3% (1) were the medical condition associated with intervention group. Alcohol consumption, tobacco chewing and smoking were the most frequently associated social habits among the both control and intervention group. The demographics and clinical characteristics is summarized in Table 1.

Parameters Frequency Percentage
Control group 33 50%
Interventional group 33 50%
Groups Control group Intervention group
Variables Frequency Percentage Frequency Percentage
Age Control (Mean =44.4±10.57) Intervention (Mean= 43.8±12.6) 18-30 Years 3 9.1% 5 15.1%
31-40 Years 10 30.3% 9 27.3%
41-50 Years 9 27.3% 9 27.3%
51-65 Years 11 33.3% 10 30.3%
Gender Female 14 42.4% 15 45.5%
Male 19 57.6% 18 54.5%
Habits Smoking 5 15.2% 6 18.2%
Alcohol 10 30.3% 8 24.2%
Tobacco 5 15.2% 8 24.2%
No habits 13 39.4% 11 33.3%
Diagnosis DVT 1 3% 3 9.1%
Unstable angina 4 12.1% 5 15.2%
MI 5 15.2% 7 21.2%
Cerebrovascular disease 2 6.1% 4 12.1%
Rheumatic heart disease 7 21.2% 3 9.1%
Vascular surgery, prosthetic heart valve 4 12.1% 3 9.1%
Defibrillation syndrome 3 9.1% 1 3%
PE 3 9.1% 2 6.1%
Stroke 2 6.1% 2 6.1%
Congestive heart failure 1 3% 1 3%
IHD 1 3% 2 6.1%

 

On assessment of medication adherence in the control group, 6.1% (2) were highly adherent followed by 54.5% (18) moderately adherent and 39.4% (13) low adherent at baseline. At follow up after 2 months, 6.1% (2) highly adherent, 42.45 (14) moderately adherent and 51.5% (17) low adherent in the control group. Likewise, in the intervention group, only 3% (1) patients were highly adherent, 51.5% (17) moderately adherent and 45.45 (15) low adherent at baseline. But at follow up after 2 months, 27.3% (9) patients were highly adherent followed by 51.5% (17) moderately adherent and 21.2% (7) low adherent (Table 2). Also, the major cause for non-adherence was found to be forgetfulness (at baseline -control: 42.4%, intervention 39.4%), (at follow up- control: 45.5%, intervention: 45.5%), stopping the medication once felt better (at baseline -control: 39.4%, intervention 36.4%), (at follow up- control: 33.3%, intervention: 30.3%) and lack of proper knowledge about regimen (at baseline -control: 18.2%, intervention 24.2%), (at follow up- control: 21.2%, intervention: 24.2%) as shown in Table 2.

Parameters Control Intervention
Causes for non-adherence At baseline At follow up At baseline At follow up
Forgetfulness 42.4% (14) 45.5% (15) 39.4% (13) 45.5% (15)
Stopping medication once felt better 39.4% (13) 33.3% (11) 36.4% (12) 30.3% (10)
Lack of knowledge about regimen 18.2% (6) 21.2% (7) 24.2% (8) 24.2% (8)

 

OAK questionnaire was evaluated at baseline as well as at follow up for both control and intervention group. The patient knowledge mean score for the control at baseline is 10.48±2.8 of which 87.9% (29) patients were having poor knowledge and only 12.1% (4) were having adequate knowledge. At the follow up patient knowledge mean score for the control is 11.94±3.0, 66.7% (22) with poor knowledge and 33.3% (11) with adequate knowledge. Patients baseline mean score of knowledge for the intervention is 11.8±2.7, 60.7% (22) with poor knowledge and 30.3% (10) adequate knowledge. The mean score of knowledge among intervention group patients at follow up is 16.8±2.5, adequate knowledge 90.9% (30) and poor knowledge 9.1% (3). At follow up, 66.7% and 9.1% were found to have poor knowledge and 33.3% and 90.9% were found to have adequate knowledge among control and intervention group respectively (Table 3).

Medication adherence
MMAS-8 Control group Intervention group
Parameters Frequency Percentage Frequency Percentage
At baseline Highly adherent (Score=8) 2 6.1% 1 3%
Moderately adherent (Score 6-8) 18 54.5% 17 51.5%
Low adherent (Score <6) 13 39.4% 15 45.4%
At follow up Highly adherent (Score=8) 2 6.1% 9 27.3%
Moderately adherent (Score 6-8) 14 42.4% 17 51.5%
Low adherent (Score <6) 17 51.5% 7 21.2%
Oral Anticoagulation Knowledge
OAK Control group Intervention group
Baseline Follow up Baseline Follow up
Adequate knowledge (score 14-20) 4 (12.1%) 11 (33.3%) 10 (30.3%) 30 (90.9%)
Poor knowledge (score 0-<14) 29 (87.9%) 22 (66.7%) 20 (60.7%) 3 (9.1%)
Mean ±SD 10.48±2.8 11.9±3.0 11.8±2.7 16.8±2.5
International Normalised Ratio (INR)
INR value Control group Intervention group
Frequency Percentage Frequency Percentage
At baseline Control (Mean ±SD) (1.74±0.8) Intervention (Mean ±SD) (1.60±1.0) Subtherapeutic range: <1- 2 25 75.7% 24 72.7%
Therapeutic range :2- 3.5 6 18.2% 5 15.2%
Supratherapeutic range >3.5 2 6.1% 4 12.1%
At follow up Control (Mean ±SD) (2.17±0.8) Intervention (Mean ±SD) (2.5±1.2) Subtherapeutic range <1- 2 21 63.6% 12 36.3%
Therapeutic range :2- 3.5 8 24.2% 12 36.4%
Supratherapeutic range: >3.5 4 12.1% 9 27.3%

 

Majority 75.7% (25) of patients in the control group were having subtherapeutic level (<1-2) of INR followed by 18.2% (6) were in therapeutic range (2- 3.5) and 6.1% (2) were supratherapeutic range (≥3.5) at baseline whereas 63.6% (21) were in subtherapeutic, 24.2% (8) in therapeutic range and 12.1% (4) in Supratherapeutic range at follow up. Likewise, for the intervention group, 72.7% (21) were in subtherapeutic, 15.2% (5) were in therapeutic range and 12.1% (4) in supratherapeutic at baseline whereas 36.4% (12) were in therapeutic, 36.3% (12) in subtherapeutic, and 27.3% (9) in supratherapeutic range at follow up (Table 2).

 

Gaps in patient awareness were determined to be one of the most significant obstacles to oral anticoagulation and were associated to decreased safety and efficacy. It is possible to improve patient outcomes by successfully controlling the determinants like patient education, prescription adherence, lifestyle modification, drug and food interactions, and INR monitoring frequently. In the present study out of 66 patients, 56.1% (37) males and 44% (29) were females with majority from the age group of 41-50 years which is in parallel to a study on anticoagulant knowledge and INR control among 225 patients where male (53%) patients were dominant in compared to female (46.6%) with the mean age of 70 years.11 According to the criteria of MMAS-8 for medication adherence, the total range of scoring is 0 to 8 where the score <6 indicates low adherence, 6-8 indicates moderately adherence and 8 indicates high adherence.12 Our study showed that at baseline both the control and intervention groups were having low adherence i.e., 39.4% (13) control and 45.4% (15) intervention. However, level of adherence gradually improved among intervention group from baseline [low adherence 45.4% (15), medium adherence 51.5% (17), high adherence 3% (1)] to follow up [low adherence 27.3% (9), medium adherence 51.5% (17), high adherence 21.2% (7)]. This improvement strongly shows importance of pharmaceutical care provided by clinical pharmacist such as patient education, awareness about medication adherence, knowledge on disease related complications, adverse effects and importance about regular check-ups. Increase level of adherence led to achieve therapeutic range of INR in majority of the patients among intervention group i.e., from 15.2% patients in therapeutic range at baseline to 36.4% in therapeutic range at follow up. Meanwhile, control group wasn’t provided with any pharmaceutical care this resulted in very poor adherence pattern at baseline [low adherence 39.4% (13), medium adherence 54.5% (18), high adherence 6.1% (2)] and at follow up [low adherence 51.5% (17), medium adherence 42.4% (14), high adherence 6.1% (2)]. As patients were not provided with any awareness by pharmacist there was no much improvement in INR therapeutic range i.e., only 18.2% patients were therapeutic range at baseline which slightly improved at follow up i.e., 24.2% achieved therapeutic range. Similarly, a Brazilian study on impact of knowledge of warfarin therapy and its relation with adherence towards therapy and INR level among 60 patients revealed that 86.7% patients were low adherent to prescribed therapy of which about 61.5% patients were found to have subtherapeutic or supratherapeutic INR range.13 Likewise, an Australian survey found that only 54.9% of total 386 atrial fibrillation participants were highly adherent to the oral anti-coagulant therapy where females were more likely to be adherent in comparison to men. Thus, significant predictors of adherence were age, gender, treatment satisfaction, lack of adequate knowledge, misuse and cost of OACs.14 A Chinese study among 170 patients who were on anticoagulation therapy for 3 months were assessed for adherence and factors associated with adherence where they found 50 patients (29.4%) were poorly adhered and 120 (70.6%) were highly adhered. Forgetting to take the medication (21.20%) and ceasing to take the medication when they feel better (9.40%) were the two main causes of poor adherence. Factors such as number of drugs, types of comorbidities, monthly income, and self-efficacy were other factors associated with the poor adherence.15 Likewise, In the present study the major cause for non-adherence was forgetfulness followed by stopping of the medication once felt better and lack of proper knowledge on rational use of anticoagulants (Table 3).

OAK questionnaire consists of 20 questions pertaining to several domains such as indication, missed dose, effects of food, other drugs and vitamins on oral anticoagulation, test for PT/INR, safety considerations. For each correct answer a score of 1 is given. OAK has been categorised into poor knowledge (score <14) and adequate knowledge (score 14-20).13 At the baseline, 87.9% patients were having poor knowledge and only 12.1% (4) were having adequate knowledge among the control group whereas 66.7% were with poor knowledge and 33.3% (11) with adequate knowledge at follow up. Similarly, 60.7% patients were with poor knowledge and 30.3% with adequate knowledge whereas the knowledge was highly increased after 2 months of post counselling which resulted in 90.9% patients with adequate knowledge and only 9.1 % were having poor knowledge. This improvement in knowledge among intervention group led in attaining huge differences in therapeutic range INR in comparison to control group. Similarly, a study in Saudi Arabia carried out a face-to-face interview for all the patients who were on anticoagulant therapy. A total of 162 patients were questioned to test their knowledge regarding anticoagulation therapy. They found that 53.1% of patients with poor knowledge out of which < 50% were medium adherence and 24% were highly adherent to the therapy. However, a controlled INR was present in 53.2% of patients with good knowledge whereas it is around 27% in patients with poor knowledge.16 Rahmani et al., conducted a study to assess the knowledge of anticoagulants using OAK questionnaire and association between level of knowledge, INR control and adverse effects among 225 patients on oral anticoagulants. A mean OAK score of 12 was obtained in which 64% had very less score. Patients with younger age and better education were able to understand and were having sufficient knowledge on anticoagulants. Patients presented with 22 bleeding episodes and 5 thrombosis where INR of 57.3% patients were therapeutic level, 25.1% at subtherapeutic, and 17.4% at supratherapeutic level.11 A prospective Malaysian study assessed the knowledge of 215 atrial fibrillation patients on anticoagulant medications using OAK questionnaire. OAK scores of 47.6±17.6 was found among the patients.17

One of the major obstacles in developing countries affecting adherence is cost of the medication. However, by providing generic medicines which are proven to have similar effect to that of branded drugs could be a great strategy to overcome the financial burden among patients. 18 Therefore, proper knowledge and low-cost therapy will improve level of adherence that would decrease unnecessary hospitalizations, therapeutic complications and mortality. Similar to our study, Ahmed H et al., carried out a cross sectional study to evaluate the association between patients’ knowledge and adherence to anticoagulants where 76.2% were found to be adherent to warfarin therapy (MMAS score 6) and only 20.45% were of high adherence (MMAS score of 8). The results of the OAK test showed a strong positive correlation with TTR (time in therapeutic range). The correlation between medication adherence and TTR as a measure of INR control was found to be statistically significant and positive.19

 

We conclude that forgetfulness, lack of knowledge, negligence and discontinuation of treatment after partial recovery were the common reasons for non-adherence. However, providing counselling to patients on importance of adherence to therapy led to compliance towards the treatment which has positive impact on surrogate marker as well as clinical outcomes. Thus, Pharmacist oriented anticoagulation clinics could be one of the milestones in future both in the inpatient and outpatient setting.

 

The present study was conducted for short period of time with a limited sample size.

 

We would show our extreme gratitude to our Co-guide Dr. Suresh V Patted (HOD, Department of Cardiology) for allowing us to conduct and guiding us throughout. Our sincere thanks to Dr. M S Ganachari (HOD, Department of Pharmacy Practice) for keen suggestions. We would like to thank the Principal of KLE College of Pharmacy, Belagavi and Medical Superintendent of Dr. Prabhakar Kore Charitable Hospital and MRC, Belagavi for their support throughout the conduct of the study.

 

The authors declare that no funds, grants or other support were received for the conduct of the study and during the preparation of this manuscript.

 

The authors declare that there is no conflict of interest.

 

CHF: Congestive Heart Failure; DOACs: Direct Oral Anticoagulants; DVT: Deep Vein Thrombosis; IHD: Ischemic Heart Disease; INR: International Normalized Ratio; IPD: Inpatient Department; MI: Myocardial Infraction; MMAS-8: Morsiky Medication Adherence Scale-8; OAC: Oral Anticoagulant; OAK: Oral Anticoagulant Knowledge; OPD: Outpatient Department; PE: Pulmonary Embolism; PT: Prothrombin Time; TTR: Time in Therapeutic Range,; VKAs: Vitamin K Antagonists.

Go
AS

Hylek
EM

Phillips
KA

Chang
Y

Henault
LE

Selby
JV

Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The An Ticoagulation and Risk Factors in atrial fibrillation (ATRIA) Study JAMA
2001
285
18
2370
5
10.1001/jama.285.18.2370 11343485

Lip
GY

Lane
DA
Stroke prevention in atrial fibrillation: A systematic review JAMA
2015
313
19
1950
62
10.1001/jama.2015.4369 Erratum in: JAMA. 2015 Aug 25;314(8):837.
25988464

Harter
K

Levine
M

Henderson
SO
Anticoagulation drug therapy: A review West J Emerg Med
2015
16
1
11
7
10.5811/westjem.2014.12.22933 25671002

Hoffman
M

Monroe
DM
Impact of non-vitamin K antagonist oral anticoagulants from a basic science perspective Arterioscler Thromb Vasc Biol
2017
37
10
1812
8
10.1161/ATVBAHA.117.306995 28798139

Akinboboye
O
Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: Is there a treatment disparity? J Multidiscip Healthc
2015 May
18
8
217
28
10.2147/JMDH.S74529 26056467

Ashorobi
D

Ameer
MA

Fernandez
R
Thrombosis StatPearls
2021 May 1

Wendelboe
AM

Raskob
GE
Global burden of thrombosis: Epidemiologic aspects Circ Res
2016
118
9
1340
7
10.1161/CIRCRESAHA.115.306841 27126645

Navarro
JL

Cesar
JM

Fernández
MA

Fontcuberta
J

Reverter
JC

Gol-Freixa
J
Morbidity and mortality in patients treated with oral anticoagulants [Morbidity and mortality in patients treated with oral anticoagulants] Rev Esp Cardiol
2007
60
12
1226
32
10.1157/13113927 18082087

Leblanc
K

Semchuk
WM

Papastergiou
J

Snow
B

Mandlsohn
L

Kapoor
V

A pharmacist checklist for direct oral anticoagulant management: Raising the bar Can Pharm J (Ott)
2018
151
2
102
6
10.1177/1715163518756926 29531627

Davis
NJ

Billett
HH

Cohen
HW

Arnsten
JH
Impact of adherence, knowledge, and quality of life on anticoagulation control Ann Pharmacother
2005
39
4
632
6
1 0.1345/aph.1E464 15713790

Rahmani
P

Guzman
CL

Blostein
MD

Tabah
A

Muladzanov
A

Kahn
SR
Patients’ knowledge of anticoagulation and its association with clinical characteristics, INR control and warfarin-related adverse events Blood
2013
122
21
1738
10.118 2/blood.V122.21.1738.1738

Morisky
DE

Green
LW

Levine
DM
Concurrent and predictive validity of a self-reported measure of medication adherence Med Care
1986
24
1
67
74
10.1097/00005650-198601000-00007 3945130

De Souza
TF

Colet
CF

Heineck
I
Knowledge and information levels and adherence to oral anticoagulant therapy with warfarin in patients attending primary health care services J Vasc Bras
2018
17
2
109
16
10.1590/1677-5449.012017 30377419

Obamiro
KO

Chalmers
L

Lee
K

Bereznicki
BJ

Bereznicki
LR
Adherence to oral anticoagulants in atrial fibrillation: An Australian survey J Cardiovasc Pharmacol Ther
2018
23
4
337
43
10.1177/1074248418770201 29658327

Song
T

Xin
X

Cui
P

Zong
M

Li
X
Factors associated with anticoagulation adherence in Chinese patients with non-valvular atrial fibrillation Patient Prefer Adherence
2021
15493
500
10.2147/PPA.S285020 33688171

Al-Omair
SF

Musallam
NA

Al-Deghaither
NY

Al-Sadoun
NA

Bayoumy
NK
Compliance with and awareness about long-term oral anticoagulant therapy among Saudi patients in a University Hospital, Riyadh, Saudi Arabia J Appl Hematol
2016
7
1
10
10.4103/1658-5127.181107

Matalqah
LM

Radaideh
K

Sulaiman
SA

Hassali
MA

Abdul
MA
An instrument to measure anticoagulation knowledge among Malaysian community: A translation and validation study of the Oral Anticoagulation Knowledge (OAK) Test Asian J Biomed Pharm Sci
2013
3
20
30

Chaudhary
RK

Philip
MJ

Santhosh
A

Karoli
SS

Bhandari
R

Ganachari
MS
Health economics and effectiveness analysis of generic anti-diabetic medication from jan aushadhi: an ambispective study in community pharmacy Diabetes Metab Syndr
2021
15
6
102303
10.1016/j.dsx.2021.102303 34626923

Ahmed
H

Saddouh
EA

Abugrin
ME

Ali
AMM

Elgdhafi
EO

Khaled
A

Association between patients’ knowledge and adherence to anticoagulants, and its effect on coagulation control Pharmacology
2021
106
5-6
265
74
10.1159/000511754 33202413